Gujarat Themis Biosyn Ltd.
Snapshot View

714.00 +7.20 ▲1.0%

31 January 2023, 12:20:00 PM
Volume: 2,819

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.gtbl.in
Market Cap 1,034.44 Cr.
Enterprise Value(EV) 1,013.72 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 36.74 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 19.38 Trailing Twelve Months Ending 2022-09
Industry PE 32.78 Trailing Twelve Months Ending 2022-09
Book Value / Share 92.19 Trailing Twelve Months Ending 2022-09
Price to Book Value 7.72 Calculated using Price: 712.00
Dividend Yield 1.54 Period Ending 2022-03
No. of Shares Subscribed 1.45 Cr. 14,528,702 Shares
FaceValue 5
Company Profile
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.The company has world-wide exports to satisfied customers, having customised facility for all products.The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+1.02%
1 Week
-5.97%
1 Month
-7.73%
3 Month
-4.06%
6 Month
+34.40%
1 Year
+60.18%
2 Year
+200.82%
5 Year
+1275.72%
10 Year
+6108.70%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 302.71 72.63 38.06 41.85 77.99 53.82 50.35
Return on Capital Employed (%) 209.07 113.74 80.38 54.67 42.22 44.88 85.96 67.89 67.91
Return on Assets (%) 26.54 29.88 31.50 24.25 18.45 24.07 45.62 35.65 37.08

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds -5 -1 4 8 12 19 42 70 103 134
Non Curr. Liab. 6 6 2 1 0 1 5 2 2 2
Curr. Liab. 15 10 9 12 8 13 24 26 32 25
Minority Int.
Equity & Liab. 16 15 15 21 20 33 71 98 137 161
Non Curr. Assets 13 11 11 13 13 25 35 25 44 53
Curr. Assets 3 3 3 8 8 8 36 73 93 107
Misc. Exp. not W/O
Total Assets 16 15 15 21 20 33 71 98 137 161

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 30 31 33 36 39 41 85 91 115 140
Other Income 0 0 0 0 0 2 2 3 4 5
Total Income 30 32 33 36 39 43 87 94 119 145
Total Expenditure -24 -25 -27 -30 -33 -34 -53 -50 -57 -70
PBIDT 7 6 6 6 6 10 34 44 62 75
Interest -1 0 0 0 0 0 -1 -1 -1 -1
Depreciation -1 -1 -1 -1 -1 -1 -1 -2 -2 -2
Taxation -1 -1 -2 -8 -11 -15 -19
Exceptional Items
PAT 5 5 5 4 4 6 24 30 44 53
Adjusted EPS 3 3 3 3 3 4 16 21 30 37

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 4 3 4 3 6 1 1 11 40
Cash Fr. Inv. -3 0 0 -1 -3 -1 -6 -3 -2 -30
Cash Fr. Finan. 2 -3 -3 -3 0 -4 5 2 -5 -14
Net Change 0 1 -1 0 0 1 0 0 3 -4
Cash & Cash Eqvt 0 1 0 0 0 1 1 1 4 0

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99
Public 25.01 25.01 25.01 25.01 25.01 25.01 25.01 25.01 25.01
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Fri, 27 Jan 2023
Board Meeting Intimation for Inter Alia To Consider The Un-Audited Standalone Financial Results For The Quarter And Nine Months Ended On 31St December 2022.
GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Friday 03rd February 2023 inter alia to consider the Un-audited Standalone Financial Results for the Quarter and nine months ended on 31st December 2022.Further in continuation of our Letter dated 26th December 2022 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Sunday 1st January 2023 which shall remain closed till the closure of trading hours on 05th February 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ("the Code") adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time.
Tue, 17 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (LODR) Regulation 2015 we would like to inform you that the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited has received below mentioned intimation / request(s) for Loss of Share Certificate(s) / issuance of duplicate share certificate(s) from the following shareholder(s):Sr. No. Name Folio No. Cert. No. Number of Shares Dist. No.From Dist. No.To1 RUMIE JAMSHED GAZDAR R001994 12114 50 2064801 2064850 2 RUMIE JAMSHED GAZDAR R001994 1498 50 1534001 1534050 We shall issue the duplicate Share Certificate(s) only after the necessary formalities are carried out by the Shareholder(s).
Tue, 17 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (LODR) Regulation 2015 we would like to inform you that the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited has received below mentioned intimation / request(s) for Loss of Share Certificate(s) / issuance of duplicate share certificate(s) from the following shareholder(s):Sr. No. Name Folio No. Cert. No. Number of Shares Dist. No.From Dist. No.To1 RATILAL U MEWADA R002030 16846 50 2301401 2301450 2 RATILAL U MEWADA R002030 16846 50 2301401 2301450 3 RATILAL U MEWADA R002030 16849 50 2301551 2301600 4 RATILAL U MEWADA R002030 16849 50 2301551 2301600 We shall issue the duplicate Share Certificate(s) only after the necessary formalities are carried out by the Shareholder(s).

Technical Scans View Details >>

Mon, 30 Jan 2023
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 252,338.06 1,036.00 -1.5%
Divi's Laboratories Ltd. 89,367.34 3,342.85 -0.7%
Cipla Ltd. 83,741.18 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. 72,084.75 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. 61,094.10 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. 52,291.51 1,523.45 -1.6%
Abbott India Ltd. 44,555.01 20,923.55 -0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 61.43 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-09 29.89 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-12 31.74 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.79 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.76 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.93 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-09 50.53 20,923.55 -0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.75 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-09 7.37 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-12 3.69 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.28 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.21 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.20 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-09 16.41 20,923.55 -0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-03 0.04 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-03 0.00 20,923.55 -0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-03 29.95 20,923.55 -0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-03 13.10 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-03 29.95 20,923.55 -0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,923.55 -0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,036.00 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,342.85 -0.7%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,024.15 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,335.00 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,291.00 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,523.45 -1.6%
Abbott India Ltd. Standalone 2022-03 798.70 20,923.55 -0.3%

FAQ's On Gujarat Themis Biosyn Ltd.

What is Guj. Themis Biosyn share price?

Can I buy Guj. Themis Biosyn shares now?

What is the Dividend Yield of Guj. Themis Biosyn?

What is the Market Cap of Guj. Themis Biosyn?

What are the key metrics to analyse Guj. Themis Biosyn?

What is the 52 Week High and Low of Guj. Themis Biosyn?

What is the trend of Guj. Themis Biosyn share price?